

9th March 2022

Eye Co Granted Ethics Committee Approval to Undertake Ground-breaking Study

Eye Co is very pleased to announce it has received Human Research Ethics Committee clearance to undertake a study to test the hypothesis that certain dietary omega oils presented in specific ratios has a positive influence in preventing the progression of early and intermediate stage Age-Related Macular Degeneration (AMD).

AMD is the leading cause of blindness afflicting around 400 million people globally. The fundamental rationale behind this study is to determine whether a simple adjustment to dietary intake can positively impact this condition before irreversible damage occurs to the retina.

Eye Co already has a significant stake in this area with its fludrocortisone technology.

Omega-3 and omega-6 are the two essential polyunsaturated fatty acids which are required for human biological function. Omega-3 promotes the production of anti-inflammatory signalling molecules whilst omega-6 promotes the production of inflammatory molecules.

Eye Co now intends to undertake a study in early AMD using calibrated doses of omega oils with anti-inflammatory ratios. This will be the **first time** such a study has been undertaken in humans. The study is expected to commence later this year and will take approximately 12 months to complete

Eye Co has filed patents globally in relation to this technology.



Peter Abrahamson
Managing Director